Kelly Bailey’s laboratory focuses on understanding the primary bone cancer Ewing sarcoma. Ewing sarcoma most commonly occurs in adolescents. The Bailey lab focuses on better understanding metastatic and relapsed Ewing sarcoma. Specifically, the team is studying the intersection of DNA damage and the anti-tumor immune response. The laboratory is interested in understanding the behavior of tumor-immune interactions in Ewing tumors that harbor additional germline defects in DNA damage repair genes.
The translational goal of the laboratory’s work is to determine logical DNA damage/immunotherapy combinations for the treatment of patients with metastatic and relapsed Ewing sarcoma. Bailey is a member of the Children’s Oncology Group (COG) Bone Tumor Committee New Agents for Ewing Sarcoma Task Force.
The Bailey laboratory values maintaining a diverse and supportive working environment.